furmonertinib
-
Newtown Square’s Arrivent Plans Public Stock Offering to Fund Cancer Drug
ArriVent Biopharma in Newtown Square plans to initiate a public stock offering to raise between $137.5 million and $160 million for the development and launch…
-
ArriVent in Newtown Square raises $155M for Cancer Drug Trial
Two Delaware County life science firms are leading the way this year in equity financing. A cancer treatment drug being developed by ArriVent Biopharma in…
-
Newtown Square’s ArriVent Has Stock Sale for Cancer Drug
A Newtown Square biopharmaceutical company, ArriVent, has raised $110 million in a private stock sale to bring cancer medicines approved in China to the U.S.…
-
ArriVent Launches in Newtown Square With Plans for New Cancer Drug
There’s a new biopharmaceutical company in town, specifically, in Newtown Square, writes John George for the Philadelphia Business Journal. ArriVent Biopharma of Newtown Square launched…


























